Orchestra BioMed Holdings, Inc. Ordinary Shares

Day range

—

Open

—

Prev close

$5.70

Volume

0

Market cap

$350.28M

Shares out

61.45M

P/E

—

P/S

10.95

P/B

18.13

P/FCF

—

ROE

-308.3%

ROA

-51.5%

Debt/Equity

1.80

Div yield

0.00%

As of Nov 9, 2026

• Underwriting agreementNov 9, 2026

  On November 5, 2026, Orchestra BioMed Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. and TD Securities (USA) LLC as representatives of the several underwriters named therein. The Underwriting Agreement contains customary representations, warranties and covenants, indemnification provisions and termination provisions.

• Partnership or collaborationOct 1, 2026

  The BACKBEAT Trial is being conducted with Medtronic plc (NYSE: MDT), the Company's strategic collaborator for the BACKBEAT Trial and, subject to regulatory approval, for the commercialization of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of medication.

• Investor presentationSep 8, 2026

  A copy of a slide presentation that Orchestra BioMed Holdings, Inc. (the "Company") uses at investor and industry conferences and presentations is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. Additionally, the Company has posted the slide presentation on its website at https://investors.orchestrabiomed.com under the Investor Relations section.

• Annual meeting resultsJun 23, 2026

  On June 23, 2026, Orchestra BioMed Holdings, Inc. held its 2026 Annual Meeting of Stockholders. Based on the votes set forth above, the Company's stockholders elected each of the three nominees set forth above to serve as a Class III director of the Company until the Company's 2029 annual meeting of stockholders and until such director's respective successor is duly elected and qualified.

• Executive compensation changeFeb 13, 2026

  On February 12, 2026, the Board also approved a revised restricted stock unit ('RSU') vesting schedule, under which RSU awards will vest over three years in four equal installments: 25% at 18 months, 25% at 24 months, 25% at 30 months, and 25% at 36 months.

Days to cover

9.7

Short interest

2.55M

Avg volume

263.11K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Orchestra BioMed Announces Pricing of Public Offering
  positiveGlobeNewswire Inc.· Nov 5, 2026
• Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
  neutralZacks Investment Research· Nov 5, 2026
• Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
  positiveGlobeNewswire Inc.· Jun 29, 2026
• Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
  positiveGlobeNewswire Inc.· Feb 19, 2026
• Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
  positiveGlobeNewswire Inc.· Oct 27, 2025